Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
41.71
+0.28 (+0.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
February 26, 2024
Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for...
Via
Benzinga
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Via
InvestorPlace
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Via
Benzinga
Exposures
Product Safety
Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst
February 15, 2024
Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
February 13, 2024
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.
Via
Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
January 29, 2024
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
Via
Benzinga
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
January 16, 2024
Roche's Tecentriq SC, the EU's first subcutaneous PD-(L)1 immunotherapy, approved for faster, 7-minute injections
Via
Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival.
Via
Benzinga
Exposures
Product Safety
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
January 10, 2024
Cramer shared his insights during his attendance at JPMorgan's healthcare conference,
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
Last year wasn't great for either stock, but that's no reason to ignore them.
Via
The Motley Fool
Why Is LumiraDx (LMDX) Stock Down 13% Today?
January 08, 2024
LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday!
Via
InvestorPlace
3 Great Foreign Companies to Invest in Right Now
January 08, 2024
These international companies can bring a helpful new flavor to your investment portfolio.
Via
The Motley Fool
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
January 02, 2024
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.
Via
Benzinga
Exposures
COVID-19
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
December 21, 2023
Which weight-loss stocks are good buys today?
Via
The Motley Fool
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...
Via
Benzinga
Exposures
Product Safety
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
December 20, 2023
It isn't the first drugmaker to partner with the chipmaker, and it won't be the last.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
December 15, 2023
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering.
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.
Via
InvestorPlace
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
December 11, 2023
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen...
Via
Benzinga
Why Viking Therapeutics Was Crushing It This Week
December 08, 2023
Nowadays, it's good to be a developer of next-generation weight loss drugs.
Via
The Motley Fool
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer
Via
Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in...
Via
Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
December 05, 2023
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti
Via
Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
Via
Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
December 04, 2023
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.
Via
Investor's Business Daily
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Roche Holding AG (OTC: RHHBY) has agreed to
Via
Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.